Dexamethasone and COVID-19 Inpatient Mortality
NCT04926571
Completed
The study aims to assess the effectiveness of dexamethasone initiation to reduce the risk of inpatient mortality within 28 days among US patients hospitalized with COVID-19 diagnosis or SARS-CoV-2 infection, overall and stratified by COVID-19 severity subgroups.
Gender:
ALL
Ages:
All
Trial Updated:
04/13/2023
Locations: Aetion, Inc., New York, New York
Conditions: Coronavirus
Register for Updates
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
NCT03465540
Terminated
Evaluate the safety and tolerability of AMG 397. Estimate the maximum tolerated doses (MTDs) and/or biologically active doses.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/06/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama +20 locations
Conditions: Multiple Myeloma, Acute Myeloid Leukemia, AML, NHL, Non-Hodgkins Lymphoma, Myelodysplastic Syndrome, MDS
Register for Updates
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
NCT00005585
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which regimen of combination chemotherapy is more effective for childhood acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is comparing different regimens of combination chemotherapy to see how well they work in treating children with acute lymphoblastic leukemia.
Gender:
ALL
Ages:
Between 1 year and 9 years
Trial Updated:
04/04/2023
Locations: Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama +122 locations
Conditions: Leukemia
Register for Updates
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00005596
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which regimen of chemotherapy is more effective for acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is comparing four regimens of combination chemotherapy to see how well they work in treating children with newly diagnosed acute lymphoblastic leukemia.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
04/04/2023
Locations: Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama +122 locations
Conditions: Leukemia
Register for Updates
Use of Dexamethasone in Pediatric Asthma Exacerbations
NCT02192827
Completed
The purpose of this study is to compare the efficacy of a single dose of dexamethasone vs. two doses of dexamethasone in mild and moderate asthma exacerbations pediatric patients.
Gender:
ALL
Ages:
Between 2 years and 20 years
Trial Updated:
03/29/2023
Locations: Women and Children's Hospital Of Buffalo, Buffalo, New York
Conditions: Asthma
Register for Updates
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
NCT00783367
Completed
Pre-clinical data and recently published clinical data suggest a synergistic effect between lenalidomide and dexamethasone. We hypothesize that a combination of lenalidomide-dexamethasone can overcome rituximab resistance. To determine the response rate to lenalidomide and dexamethasone plus rituximab therapy in subjects with recurrent small B-cell non-Hodgkin lymphoma who have had lymphoma progression within 6 months of being treated with rituximab alone or with a rituximab-containing regimen,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2023
Locations: University of Pennsylvania; Abramson Cancer Center; Lymphoma Program, Philadelphia, Pennsylvania
Conditions: Follicular Lymphoma, Marginal Zone B-Cell Lymphoma, MALT Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue, Lymphoma, Small Lymphocytic, Waldenstrom Macroglobulinemia, Mantle-Cell Lymphoma
Register for Updates
Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
NCT03411031
Terminated
The purpose of this study is determine Time-to-Progression with elotuzumab plus lenalidomide when elotuzumab is added to multiple myeloma participants with serologic relapse/progression while receiving lenalidomide maintenance for each study arm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2023
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Multiple Myeloma
Register for Updates
Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma
NCT01794520
Completed
The Phase 1 primary objectives of this study were to assess the safety profile, characterize pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and recommended Phase 2 dose (RPTD) of ABT-199 (venetoclax) when administered in participants with relapsed or refractory multiple myeloma. This study also assessed the safety profile and PK of venetoclax in combination with dexamethasone in participants with t(11;14)-positive multiple myeloma. The Phase 2 primary obj... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/16/2023
Locations: Mayo Clinic - Scottsdale /ID# 75808, Scottsdale, Arizona +28 locations
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
Steroid Use in Non-RSV Bronchiolitis
NCT04221087
Terminated
The proposed study is a pilot randomized control trial to determine the efficacy of dexamethasone use in hospitalized children who are less than 2 years of age with non-respiratory syncytial virus (RSV) bronchiolitis admitted to the University of Pittsburgh Medical Center (UPMC) Children's Hospital of Pittsburgh from February 1 to May 31, 2022. It is hypothesized that the use of standard airway-dose steroids (0.6mg/kg dexamethasone) will improve the clinical outcome of children hospitalized for... Read More
Gender:
ALL
Ages:
Between 1 day and 2 years
Trial Updated:
03/15/2023
Locations: UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Bronchiolitis, Viral
Register for Updates
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT01256398
Completed
This phase II clinical trial studies how well dasatinib followed by stem cell transplant works in treating older patients with newly diagnosed acute lymphoblastic leukemia. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Monoclonal antibodies, such as alemtuzumab, may interfere with the ability of cancer cells to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2023
Locations: Stanford Cancer Institute Palo Alto, Palo Alto, California +100 locations
Conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Register for Updates
Transverse Abdominus Plane Block Study
NCT05216055
Withdrawn
Study the effect of laparoscopic guided TAP block on opioid consumption and associated costs using a mixture of dexmedetomidine, dexamethasone, and ropivacaine versus Liposomal bupivacaine (Exparel®) in patients who undergo elective minimally invasive colorectal surgery.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/03/2023
Locations: Rocky Mountain Regional VA Medical Center, Aurora, Colorado +2 locations
Conditions: Colorectal Disorders, Surgery
Register for Updates
Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
NCT04895410
Terminated
Multiple myeloma (MM) accounts for more than 10% of all blood cancers and 1% of all cancers. The purpose of this study is to assess how safe lemzoparlimab is and how lemzoparlimab moves through the body of adult participants with MM when given with or without dexamethasone, and in combination with other anti-myeloma regimens. Adverse events and change in disease activity will be assessed. Lemzoparlimab is an investigational drug being developed for the treatment of relapsed/refractory (R/R) MM.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2023
Locations: Sylvester Comprehensive Cancer Center /ID# 228817, Miami, Florida +31 locations
Conditions: Multiple Myeloma
Register for Updates